Biologic Therapies in Severe Uncontrolled Asthma, Review of the Most Important Randomized Controlled Trials

Abstract

This thesis reviews the currently approved biologic therapies for severe uncontrolled asthma, with a focus on their mechanisms of action, clinical efficacy, safety profiles, and cost-effectiveness. The study examines biologics targeting IgE, IL-5, IL-4 receptor, and thymic stromal lymphopoietin (TSLP), including omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab. Emphasis is placed on evidence derived from major randomized controlled trials and real-world studies evaluating treatment outcomes such as exacerbation reduction, lung function improvement, oral corticosteroid sparing, and quality of life.